NervGen Pharma NGENF Stock
NervGen Pharma Price Chart
NervGen Pharma NGENF Financial and Trading Overview
| NervGen Pharma stock price | 5.63 USD |
| Previous Close | 5.63 USD |
| Open | 5.3 USD |
| Bid | 5.64 USD x 500000 |
| Ask | 5.74 USD x 100000 |
| Day's Range | 5.3 - 5.81 USD |
| 52 Week Range | 1.5 - 6.3 USD |
| Volume | 27.43K USD |
| Avg. Volume | 143.4K USD |
| Market Cap | 445.97M USD |
| Beta (5Y Monthly) | 0.756 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
NGENF Valuation Measures
| Enterprise Value | 446.2M USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -17.705 |
Trading Information
NervGen Pharma Stock Price History
| Beta (5Y Monthly) | 0.756 |
| 52-Week Change | 170.67% |
| S&P500 52-Week Change | 12.81% |
| 52 Week High | 6.3 USD |
| 52 Week Low | 1.5 USD |
| 50-Day Moving Average | 4.41 USD |
| 200-Day Moving Average | 3.11 USD |
NGENF Share Statistics
| Avg. Volume (3 month) | 143.4K USD |
| Avg. Daily Volume (10-Days) | 221.45K USD |
| Shares Outstanding | 79.21M |
| Float | 65.45M |
| Short Ratio | N/A |
| % Held by Insiders | 21.28% |
| % Held by Institutions | 0% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2024 |
| Most Recent Quarter (mrq) | September 30, 2025 |
| Next Fiscal Year End | December 31, 2025 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -88.77% |
| Return on Equity (ttm) | -820.11% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -25201288 USD |
| Net Income Avi to Common (ttm) | -25572946 USD |
| Diluted EPS (ttm) | -0.26 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 11.36M USD |
| Total Cash Per Share (mrq) | 0.15 USD |
| Total Debt (mrq) | 33.23K USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.79 |
| Book Value Per Share (mrq) | -0.0289504 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -16761550 USD |
| Levered Free Cash Flow (ttm) | -7214422 USD |
Profile of NervGen Pharma
| Country | United States |
| State | BC |
| City | Vancouver |
| Address | 112-970 Burrard Street |
| ZIP | V6Z 2R4 |
| Phone | 778-731-1711 |
| Website | https://www.nervgen.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.
Q&A For NervGen Pharma Stock
What is a current NGENF stock price?
NervGen Pharma NGENF stock price today per share is 5.63 USD.
How to purchase NervGen Pharma stock?
You can buy NGENF shares on the OTC Markets OTCQB exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for NervGen Pharma?
The stock symbol or ticker of NervGen Pharma is NGENF.
Which industry does the NervGen Pharma company belong to?
The NervGen Pharma industry is Biotechnology.
How many shares does NervGen Pharma have in circulation?
The max supply of NervGen Pharma shares is 79.21M.
What is NervGen Pharma Price to Earnings Ratio (PE Ratio)?
NervGen Pharma PE Ratio is 0.00000000 now.
What was NervGen Pharma earnings per share over the trailing 12 months (TTM)?
NervGen Pharma EPS is 0 USD over the trailing 12 months.
Which sector does the NervGen Pharma company belong to?
The NervGen Pharma sector is Healthcare.